Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATN-103 q4wks · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ATN-103 10 mg q4wks | BIOLOGICAL | ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections. |
| ATN-103 30 mg q4wks | BIOLOGICAL | ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections. |
| ATN-103 80 mg q4wks | BIOLOGICAL | ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections. |
| ATN-103 10 mg q8wks | BIOLOGICAL | ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections. |
| ATN-103 80 mg q8wks | BIOLOGICAL | ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections. |
Inclusion Criteria: * Meets the ACR 1987 revised criteria for classification of Rheumatoid Arthritis (RA). * ACR functional class I through III. * Active RA at the time of screening and at baseline consisting of = 6 swollen and = 6 tender joints at least. * hs-CRP level = 8 mg/L. * Must be receivin...
Top 20 of 28 competitors
ATN-103 q4wks is an investigational monoclonal antibody being studied for the treatment of rheumatoid arthritis. It is administered every four weeks. The drug is in Phase 1 clinical development and has not been approved by regulatory authorities.
ATN-103 q4wks is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical development for rheumatoid arthritis.
ATN-103 q4wks is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of rheumatoid arthritis.
ATN-103 q4wks has one completed clinical trial, NCT01007175, which studied multiple ascending doses of the drug in Japanese subjects with rheumatoid arthritis. The trial enrolled 60 participants and was a randomized, double-blind, controlled study.
ATN-103 q4wks refers to the dosing regimen of ATN-103 administered every four weeks. The drug is a monoclonal antibody being developed by Sanofi for rheumatoid arthritis. It is currently in Phase 1 clinical development.